Can-fite Biopharma Ltd.

Shira Cohen

Pnina Fishman

Inbal Itzhak

Motti Farbstein

Provided is an A3 adenosine receptor (AAR) ligand for use in achieving at least one fat loss effect selected from: reducing weight of the subject; reducing body fat mass in the subject; treating obesity in the subject and inhibiting adipocytes proliferation in a subject. The disclosure also concerns pharmaceutical compositions, methods of treatment and kits comprising the AAR ligand.

A3 adenosine receptor ligand for use for achieving a fat loss effect

Provided is an AAR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Further provided is the use of AAR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits including pharmaceutical compositions including the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. Further provided is the use of an AAR agonist, such as 2-Chloro-N-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (CI-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).

Method for treating fibrotic liver tissue using Cl-IB-MECA

Provided is an AAR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Further provided is the use of AAR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits including pharmaceutical compositions including the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. Further provided is the use of an AAR agonist, such as 2-Chloro-N-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (Cl-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).

Method for treating NASH accompanied by fibrosis using Cl-IB-MECA

The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an AAR agonist. A preferred AAR agonist disclosed herein is Cl-IB-MECA.

Growing community of inventors

Hod Hasharon, Israel

Shira Cohen